TRON-DAO
6.4.2022 09:40:09 CEST | Business Wire | Press release
TRON founder Justin Sun has recently purchased the complete set of the crypto artworks "Twelve Digital Zodiac Heads" at the Twelve Digital Zodiac Heads Special Auction hosted by Metapoly XM, a brand under Poly Auction (Xiamen).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220403005114/en/
The "Twelve Digital Zodiac Heads" is the one and only NFT art collection that draws inspiration from China's Zodiac Heads, which was purchased on March 31 at a hammer price of around ¥9,832,500. Shortly after the auction, Justin Sun stated to the public that he would donate this collection in the future for a broader audience to enjoy. It is also believed that one of the animal heads in this collection will soon be listed on APENFT Marketplace for auction and introduced as rare, special-breed horses into WIN NFT HORSE, a horse racing game co-launched by TRON, the APENFT Foundation, and WINKLink.
The twelve zodiac animals are an epitome of Chinese folk culture and the unique philosophy of the Chinese nation. According to traditional Chinese culture, every newborn is assigned an auspicious animal based on their birth year. These animals are unchangeable marks that follow each Chinese throughout their life. They serve as a bond to maintain the national feelings and the Chinese culture. And of all the physical embodiment of these symbols, the Twelve Old Summer Palace bronze heads are the most precious.
Gathering the twelve bronze heads in the metaverse marks another major endeavor made by digital technology, represented by blockchain, in the cultural and art sphere. In the context of social informatization and digitization, digital propagation and protection of traditional culture will embrace wider applications in order to reproduce time-honored artworks in the digital world and diversify people's experience in art appreciation.
As a trailblazer in digital technology, Justin Sun also has serious clout in the realm of top-notch art collections. Through clinching a myriad of artworks created both by art masters and emerging digital artists on major trading platforms, Justin has managed to build an empire incorporating art, investment, finance, and more. His collections include works by Pablo Picasso, Andy Warhol, Giacometti, Beeple, and Pak, the latter two being the two most valuable crypto artists worldwide. In addition, Justin Sun has donated a number of well-known works, including Le Nez and Femme nue couchée au collier(Marie-Thérèse) , to organizations such as the APENFT Foundation to support the development of digital art.
APENFT is backed by the underlying technology of top-notch blockchains TRON with support from the world's largest distributed storage system Bittorrent File System (BTFS), dedicated to promoting the creator economy and fostering the integration of finance, culture and art in Metaverse. Its APENFT Marketplace, based on the TRON, will also be launched shortly.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220403005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom